Mga Batayang Estadistika
| CIK | 1684144 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zomedica Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11 |
|
| August 6, 2025 |
EXHIBIT 99.1 Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth Zomedica posts record year-over-year revenue for 18th straight quarter! ANN ARBOR, MI / ACCESSWIRE / August 6, 2025 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 6, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 30, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 30, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. |
|
| May 15, 2025 |
EXHIBIT 99.1 Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth ANN ARBOR, MI / ACCESSWIRE / May 15, 2025 / Zomedica Corp. (OTCQB: ZOMDF) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| May 13, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 30, 2025 |
EXHIBIT 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE This Confidential Separation Agreement and Release ("Agreement") is made by and between Scott Jordan ("Employee") and Zomedica Inc. ("Zomedica"). WHEREAS, Employee was an employee of Zomedica from January 1, 2025, until Employee’s employment ended on April 25, 2025; WHEREAS, the parties now desire to amicably end Employee's employment with |
|
| April 30, 2025 | ||
| April 30, 2025 | ||
| April 30, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 14, 2025 |
EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth ANN ARBOR, MI / ACCESSWIRE / March 13, 2025 / Zomedica Corp. (OTCQB: ZOMDF) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and |
|
| March 13, 2025 |
EXHIBIT 99.1 Tony Frouge Chief Regulatory Officer New York Stock Exchange 11 Wall Street New York, NY 10005 T + 1 212 656 2133 [email protected] March 4, 2025 Mr. Larry Heaton Chief Executive Officer Zomedica Corp. 100 Phoenix Drive, Suite 125 Ann Arbor, Michigan 48108 Dear Mr. Heaton: This will confirm our communication with you and your team that NYSE Regulation has determined to commence pro |
|
| March 13, 2025 |
Offer letter, dated December 29, 2021, among Zomedica Inc., Zomedica Corp., and Tony Blair Exhibit 10.23 <.� ZOMEDICA'. December 29, 2021 Mr. Tony Blair 29265 Sivey Road Richwood, Ohio 43344 Dear Tony: On behalf of Zomedica Inc., I am pleased to extend a formal offer of employment to you as Vice President of Operations. This letter will detail our conditional offer of employment. • Position. You will be appointed as Executive Vice President of Operations and will report to the Chief Exe |
|
| March 13, 2025 |
Insider Trading Policy (Included in Code of Ethics Policy) EXHIBIT 19.1 AMENDED AND RESTATED CODE OF ETHICS AND BUSINESS CONDUCT ZOMEDICA CORP. August 1, 2024 Purpose and Scope. The Board of Directors (the “Board”) of Zomedica Corp. (the “Company”) established this Code of Ethics and Business Conduct (the “Code”) to aid our directors, officers, and employees in making ethical and legal decisions when conducting the Company’s business and performing their |
|
| March 13, 2025 |
EXHIBIT 21.1 |
|
| March 13, 2025 |
Offer letter, dated April 19, 2022, among Zomedica Inc., Zomedica Corp., and Karen Dehaan-Fullerton Exhibit 10.22 |
|
| March 13, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Common Shares of Zomedica Corp. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 5, 2025 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Zomedica Corp. Announces Transition to OTCQB Market Zomedica’s ticker symbol will change to ZOMDF ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that i |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 19, 2024 |
EXHIBIT 10.1 |
|
| December 19, 2024 |
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer EXHIBIT 99.1 Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer Seasoned executive brings a broad skill set to Zomedica’s leadership team. ANN ARBOR, MI / ACCESSWIRE / December 19, 2023 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 19, 2024 |
EXHIBIT 10.1 |
|
| November 8, 2024 |
EXHIBIT 99.1 Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. |
|
| November 7, 2024 |
Stock Appreciation Rights Agreement (Employees) EXHIBIT 10.3 Stock Appreciation Rights Agreement This Stock Appreciation Rights Agreement (this "Agreement") is made and entered into as of [DATE] by and between Zomedica Corp., a corporation organized under the laws of the Province of Alberta (the "Corporation") and [EMPLOYEE NAME] (the "Participant"). Grant Date: Number of SARs: Exercise Price per SAR: Expiration Date: 1.Grant of SARs. 1.1Grant. |
|
| November 7, 2024 |
Stock Appreciation Rights Agreement (Directors) EXHIBIT 10.4 Stock Appreciation Rights Agreement This Stock Appreciation Rights Agreement (this "Agreement") is made and entered into as of [DATE] by and between Zomedica Corp., a corporation organized under the laws of the Province of Alberta (the "Corporation") and [NON-EMPLOYEE DIRECTOR NAME] (the "Director"). Grant Date: Number of SARs: Exercise Price per SAR: Expiration Date: 1.Grant of SARs. |
|
| November 7, 2024 |
Stock Appreciation Rights Plan EXHIBIT 10.5 ZOMEDICA CORP. 2024 STOCK APPRECIATION RIGHTS PLAN 1.Purpose; Eligibility. 1.1General Purpose. The purposes of the Zomedica Corp. 2024 Stock Appreciation Rights Plan (the "Plan") are to (a) enable Zomedica Corp., a corporation organized under the laws of the Province of Alberta (the "Corporation"), and any Affiliate to attract and retain the types of Employees, Consultants and Directo |
|
| October 9, 2024 |
100 Phoenix Drive, Suite 125, Ann Arbor, MI 48108 | P: +1 734-369-2555 | www.zomedica.com October 1, 2024 Division of Corporate Finance Office of Life Sciences United States Securities and Exchange Commission Washington D. |
|
| August 14, 2024 |
EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic devic |
|
| August 14, 2024 |
Stock Appreciation Rights Agreement (Employees) Exhibit 10.3 Stock Appreciation Rights Agreement This Stock Appreciation Rights Agreement (this "Agreement") is made and entered into as of [DATE] by and between Zomedica Corp., a corporation organized under the laws of the Province of Alberta (the "Corporation") and [EMPLOYEE NAME] (the "Participant"). Grant Date: Number of SARs: Exercise Price per SAR: Expiration Date: 1.Grant of SARs. 1.1Grant. |
|
| August 14, 2024 |
Consulting Agreement, dated August 14, 2024, between Zomedica Inc. and Peter Donato EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of August 14, 2024 (the “Effective Date”), between ZOMEDICA INC. (the “Company”) and PETER DONATO (“Consultant”). 1. Services. Consultant is engaged to perform consulting services related to the Company’s historical and/or prospective accounting and/or securities reporting practices and procedures and |
|
| August 14, 2024 |
Separation Agreement, dated August 14, 2024, between Zomedica Inc. and Peter Donato EXHIBIT 10.2 SEPARATION AGREEMENT THIS AGREEMENT dated as of August 14, 2024 (“Agreement”) is made by and between Zomedica Corp. (the “Company”) and Peter Donato (“Executive”). WHEREAS, Executive is employed as the Chief Financial Officer of the Company and the Company’s wholly owned subsidiary, Zomedica Inc., WHEREAS, the parties wish to enter into this Agreement regarding their separation, subje |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 14, 2024 |
Stock Appreciation Rights Agreement (Directors) Exhibit 10.4 Stock Appreciation Rights Agreement This Stock Appreciation Rights Agreement (this "Agreement") is made and entered into as of [DATE] by and between Zomedica Corp., a corporation organized under the laws of the Province of Alberta (the "Corporation") and [NON-EMPLOYEE DIRECTOR NAME] (the "Director"). Grant Date: Number of SARs: Exercise Price per SAR: Expiration Date: 1.Grant of SARs. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration No. |
|
| July 3, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zomedica Corp. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 4 |
|
| July 3, 2024 |
EXHIBIT 10.1 ZOMEDICA CORP. AMENDED AND RESTATED STOCK OPTION PLAN 1. The Plan A stock option plan (the “Plan”), pursuant to which options to purchase common shares, or such other shares as may be substituted therefor (“Shares”), in the capital of Zomedica Corp. (the “Corporation”) may be granted to the directors, officers and employees of the Corporation and its subsidiaries (as hereinafter defin |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2024 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. |
|
| May 9, 2024 |
Offer letter, dated November 6, 2023, among Zomedica Inc., Zomedica Corp., and Russell Kevin Klass Exhibit 10.3 October 20, 2023 R. Kevin Klass 2004 N. Steele Circle Mesa, AZ 85207 Dear Kevin: On behalf of Zomedica Inc., I am pleased to extend an offer of employment to you for the full-time position of Senior Vice President, Sales, reporting to the CEO. Start Date. Your proposed start date is November 6, 2023. Base Salary. Your bi-weekly salary will be $10,961.54 (equivalent to $285,000 per yea |
|
| May 9, 2024 |
EXHIBIT 99.1 Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity Performance Sets New Record for First Quarter Revenue ANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products f |
|
| April 29, 2024 | ||
| April 29, 2024 |
FORM 10-K Annual Report April 26, 2024 Dear Zomedica Shareholders, At Zomedica, our mission remains simple - bring innovative technologies to market that help veterinarians better care for the animals we love and better take care of the business side of their practices as well. |
|
| April 26, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat |
|
| April 26, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 4, 2024 |
EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic devic |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| April 1, 2024 |
Exhibit 10.19 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (this “Amendment”) is entered into effective as of the 1st day of April, 2024, by and between Zomedica Inc., a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the city of Ann Arbor, MI (“Corporation”), Zomedica Corp., a body corporate dul |
|
| April 1, 2024 |
Exhibit 21.1 Subsidiaries of Registrant Zomedica Inc., a Delaware corporation HMT High Medical Technologies (Japan) Co., Ltd., a Japanese company NeoPulse GmbH, a Swiss Company PVT NeoPulse Acquisition GmbH, a Swiss Company Zomedica Biotechnologies, LLC Structured Monitoring Products, Inc., a Florida corporation |
|
| April 1, 2024 |
Exhibit 10.20 April 1, 2024 Peter Donato 7625 Misty Spring Court Mason, OH 45040 RE:Amendment to your March 14, 2023 offer letter (“Offer Letter”) Dear Peter: In recognition of the services that you have provided to Zomedica, and in consideration for your continued service, I am pleased to extend this letter of amendment to your Offer Letter. Effective upon your countersignature below, the followi |
|
| April 1, 2024 |
Exhibit 97.1 ZOMEDICA CORP. CLAWBACK POLICY Introduction The Board of Directors (the "Board") of Zomedica Corp. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability. The Board has therefore adopted this Clawback Policy (the “Policy”), which provides for the recovery of certain inc |
|
| April 1, 2024 |
Exhibit 10.11 LICENSE AGREEMENT This License Agreement (the “License Agreement,” “License” or “Agreement”) is dated as of November1, 2021, and entered into by and between The Wheelership LLC, a New York limited liability company (“Licensor”), and Assisi Animal Health LLC, a Delaware limited liability company, (“Licensee”), and together with the Licensor, the “Parties” or individually, as a (“Party |
|
| April 1, 2024 |
Exhibit 10.12 INDEMNITY AGREEMENT This Indemnity Agreement is entered into as of this 22nd day of December, 2022 by and between Zomedica Corp., a corporation incorporated under the laws of the Province of Alberta, Canada (the “Corporation”) and [board member/officer name], an individual residing in [city/state/province] (the “Indemnified Party”). RECITALS WHEREAS, the Indemnified Party has agreed |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 15, 2024 |
Zomedica Provides Corporate NYSE American Listing Update EXHIBIT 99.1 Zomedica Provides Corporate NYSE American Listing Update ANN ARBOR, MI / ACCESSWIRE / March 13, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it is continuing dialogue with senior regulatory staff at the NYSE American |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission File (IRS Employer of in |
|
| February 20, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement |
|
| February 6, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 31, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| January 26, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| January 24, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| January 17, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| January 17, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statem |
|
| January 5, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File N |
|
| November 13, 2023 |
EXHIBIT 99.1 Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company off |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. |
|
| November 13, 2023 |
Exhibit 21.1 Subsidiaries of Registrant Zomedica Inc., a Delaware corporation HMT High Medical Technologies (Japan) Co., Ltd., a Japanese company NeoPulse GmbH, a Swiss Company PVT NeoPulse Acquisition GmbH, a Swiss Company Qorvo Biotechnologies, LLC Structured Monitoring Products, Inc., a Florida corporation |
|
| October 10, 2023 |
EXECUTION VERSION EXHIBIT 10.1 In this document, “[***]” indicates that certain confidential information has been redacted from this document because it is both (i) not material to investors and (ii) likely to cause competitive harm to the Company if publicly disclosed. LLC MEMBERSHIP INTEREST PURCHASE AGREEMENT BY AND BETWEEN QORVO US, INC. AND ZOMEDICA INC. October 4, 2023 TABLE OF CONTENTS Page |
|
| October 10, 2023 |
CONFIDENTIAL EXECUTION VERSION EXHIBIT 10.2 In this document, “[***]” indicates that certain confidential information has been redacted from this document because it is both (i) not material to investors and (ii) likely to cause competitive harm to the Company if publicly disclosed. FIRST AMENDMENT TO BAW SENSOR SUPPLY AGREEMENT THIS FIRST AMENDMENT TO BAW SENSOR SUPPLY AGREEMENT (this “Amendment” |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 4, 2023 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 10, 2023 |
EXHIBIT 99.1 Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic devices for companion animals, today announced |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File |
|
| September 14, 2023 |
Zomedica Provides Corporate Update EXHIBIT 99.1 Zomedica Provides Corporate Update ANN ARBOR, Mich., September 13, 2023 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023 (the “NYSEA Form 8-K”), it has received formal notice from the NYSE American that it i |
|
| September 6, 2023 |
EXHIBIT 2.1 STOCK PURCHASE AGREEMENT BETWEEN SELLERS, SMP VG HOLDCO INC. AND ZOMEDICA INC. September 4, 2023 1 TABLE OF CONTENTS Page ARTICLE 1 STOCK PURCHASE; PURCHASE PRICE 1 Section 1.1 Purchase and Sale of the SMP Shares. 1 Section 1.2 Closing. 2 Section 1.3 Appointment of Seller Section 1.4 Closing Actions and Deliveries. 3 Section 1.5 Net Working Capital Adjustment. 8 ARTICLE 2 REPRESENTATIO |
|
| September 6, 2023 |
EXHIBIT 99.1 Zomedica Closes Acquisition of Structured Monitoring Products adding revolutionary VetGuardian touchless vital signs monitor to Product Portfolio ANN ARBOR, Ml / ACCESSWIRE / September 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has complet |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 4, 2023 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File N |
|
| August 10, 2023 |
EXHIBIT 99.1 Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today report |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2023 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 11, 2023 |
EXHIBIT 99.1 Zomedica Announces Record First Quarter 2023 Financial Results: Revenue up 45% to $5.5 Million; Strong 70% Gross Margin & $147.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / May 11, 2023 / Zomedica Corp. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported |
|
| May 11, 2023 |
EXHIBIT 10.1 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2023 |
Zomedica Exercises Option to Acquire Structured Monitoring Products EXHIBIT 99.1 HOLD FOR RELEASE UNTIL 6:30 am ET, May 8, 2023 Zomedica Exercises Option to Acquire Structured Monitoring Products ANN ARBOR, Ml / ACCESSWIRE / May 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), today announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc. (SMP), the makers of VetGuardian™ zero-tou |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| April 28, 2023 | ||
| April 28, 2023 |
FORM 10K Annual Report April 28, 2023 Dear Zomedica Shareholders, As we review our results for 2022, and the 18 months since I joined Zomedica, I am very pleased with the progress our team has made on multiple fronts as we continue our transformation into a market leader in point-of-care diagnostics and therapeutic products for companion animals. |
|
| April 28, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statem |
|
| April 28, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| March 17, 2023 |
Zomedica Appoints New Chief Financial Officer EXHIBIT 99.1 Zomedica Appoints New Chief Financial Officer ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato |
|
| March 17, 2023 |
EXHIBIT 10.2 March 14, 2023 Peter Donato [REDACTED] Dear Peter: On behalf of Zomedica Inc., I am pleased to extend an offer of employment to you for the position of Chief Financial Officer, reporting to me. Start Date. Your proposed start date is March 16, 2023, or an earlier date mutually agreed upon. Base Salary. Your bi-weekly salary will be $12,500.00 (equivalent to $325,000 per year). You wil |
|
| March 17, 2023 |
EXHIBIT 10.1 SEPARATION AGREEMENT THIS AGREEMENT dated as of March 16, 2023 (“Agreement”) is made by and between Zomedica Corp. (the “Company”) and Ann Marie Cotter (“Executive”). WHEREAS, Executive is employed as the Chief Financial Officer of the Company and the Company’s wholly owned subsidiary, Zomedica Inc., and WHEREAS, the parties wish to enter into this Agreement regarding their separation |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 15, 2023 |
Zomedica Corporation Reports 2022 Results: $18.9 Million EXHIBIT 99.1 Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity Revenue up 361% from 2021 through combination of acquisitions and organic growth ANN ARBOR, MI / ACCESSWIRE / March 15, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic prod |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 15, 2023 |
INDEMNITY AGREEMENT This Indemnity Agreement is entered into as of this 22nd day of December, 2022 by and between Zomedica Corp. |
|
| March 15, 2023 |
Exhibit 21.1 Subsidiaries of Registrant Zomedica Inc., a Delaware corporation HMT High Medical Technologies (Japan) Co., Ltd., a Japanese company PVT NeoPulse Acquisition GmbH, a Swiss Company NeoPulse GmbH, a Swiss Company |
|
| March 15, 2023 |
Exhibit 10.19 1 LICENSE AGREEMENT This License Agreement (the “License Agreement,” “License” or “Agreement”) is dated as of November1, 2021, and entered into by and between The Wheelership LLC, a New York limited liability company (“Licensor”), and Assisi Animal Health LLC, a Delaware limited liability company, (“Licensee”), and together with the Licensor, the “Parties” or individually, as a (“Par |
|
| February 9, 2023 |
Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022 EXHIBIT 99.1 Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022 ANN ARBOR, MI / ACCESSWIRE / February 9, 2023 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported its preliminary unaudited results for the fourth quarter and year e |
|
| February 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| January 24, 2023 |
EXHIBIT 10.1 Execution Copy In this document, “[***]” indicates that certain confidential information has been redacted from this document because it is both (i) not material to investors and (ii) likely to cause competitive harm to the Company if publicly disclosed. TRANSITION AND SUPPORT AGREEMENT This Transition and Support Agreement (this “Agreement”), dated as of January 17, 2023 (the “Effect |
|
| January 24, 2023 |
EXHIBIT 10.2 Execution Copy In this document, “[***]” indicates that certain confidential information has been redacted from this document because it is both (i) not material to investors and (ii) likely to cause competitive harm to the Company if publicly disclosed. BAW SENSOR SUPPLY AGREEMENT Between QORVO BIOTECHNOLOGIES, LLC; ZOMEDICA CORP. and ZOMEDICA INC. dated as of January 17, 2023 Execut |
|
| January 24, 2023 |
EXHIBIT 10.3 Execution Copy In this document, “[***]” indicates that certain confidential information has been redacted from this document because it is both (i) not material to investors and (ii) likely to cause competitive harm to the Company if publicly disclosed. DEVELOPMENT AND MANUFACTURING LICENSE AGREEMENT Between QORVO BIOTECHNOLOGIES, LLC; ZOMEDICA CORP. and ZOMEDICA INC. dated as of Jan |
|
| January 24, 2023 |
Press Release, dated January 18, 2023. EXHIBIT 99.1 |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 20, 2023 |
EXHIBIT 10.1 STRUCTURED MONITORING PRODUCTS, INC. Distribution Agreement This Distribution Agreement (this “Agreement”), dated as of January 13th, 2023 (the “Effective Date”), is entered into between Zomedica Inc., a Delaware corporation (“Distributor”), and Structured Monitoring Products, Inc., a Florida corporation (“Supplier”, and together with Distributor, the “Parties”, and each, a “Party”). |
|
| January 20, 2023 |
EXHIBIT 99.1 Zomedica expands relationship with Structured Medical Products and begins commercializing VetGuardian wireless monitors ANN ARBOR, MI / ACCESSWIRE / January 17, 2023 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that in cooperation with Structured Moni |
|
| November 14, 2022 |
EXHIBIT 99.1 Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-for-Sale Securities ANN ARBOR, Michigan, November 14, 2022 (ACCESSWIRE) ? Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or the ?Company?, a veterinary health company offering point-of-care diagnostics and therapeutic products for |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 14, 2022 |
Exhibit 10.2 AGREEMENT OF LEASE THIS AGREEMENT OF LEASE is made on this 9th day of October 2018, by and between GEORGIA MOTOR TRUCKING ASSOCIATION, INC., a Georgia not-for-profit corporation (hereinafter "Landlord") and REVO SQUARED, LLC, a Georgia limited liability company (hereinafter "Tenant"). WITNESSETH: ARTICLE 1 PREMISES 1.01 - In consideration of the rent hereinafter reserved and of the co |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 23, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 24, 2022 |
Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors EXHIBIT 99.1 Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and joining the Audit and Go |
|
| August 15, 2022 |
CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is made effective as of June 17, 2022, between ZOMEDICA INC. |
|
| August 15, 2022 |
Exhibit 10.3 DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 March 18, DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 DocuSign Envelope ID: F1C39DC7-6C8A-43AC-A65B-96212EC7F087 DocuSign Envelope ID: F |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-Q ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022. |
|
| August 15, 2022 |
EX-99.1 2 zomex991.htm PRESS RELEASE EXHIBIT 99.1 HOLD FOR RELEASE UNTIL 4:01 pm ET, Monday August 15, 2022 Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million of Revenue; 71% Gross Margin & $186.8 Million in Cash Revenue up 51% from 2021 Combined Revenues ANN ARBOR, Michigan, August 15, 2022 (ACCESSWIRE) – Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company, a veterina |
|
| August 15, 2022 |
Exhibit 10.4 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SEC |
|
| July 20, 2022 |
Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health EXHIBIT 99.1 Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health ANN ARBOR, MI / ACCESSWIRE / July 18, 2022 / Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or the ?Company?), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that it had acquired substantially all the assets of Assisi Animal Health LLC (?Assisi?). |
|
| July 20, 2022 |
Warrant to Purchase Common Shares dated July 15, 2022 issued to Assisi Animal Health LLC EXHIBIT 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 20, 2022 |
EXHIBIT 2.1 ASSET PURCHASE AGREEMENT BY AND AMONG ASSISI ANIMAL HEALTH LLC, THE PRINCIPAL MEMBERS OF ASSISI ANIMAL HEALTH LLC (AS DEFINED HEREIN), AAH HOLDINGS, LLC, ZOMEDICA INC. AND ZOMEDICA CORP. July 15, 2022 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 2 1.1 Certain Definitions 2 1.2 Interpretation 10 ARTICLE II. PURCHASE AND SALE OF THE ACQUIRED ASSETS 11 2.1 Purchase and Sale of the Acquir |
|
| July 11, 2022 |
EXHIBIT 99.1 Zomedica Announces New Global Manufacturing & Distribution Center ANN ARBOR, MI / ACCESSWIRE / July 7, 2022 / Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or the ?Company?), a veterinary health company offering diagnostic and therapeutic products for companion animals, is expanding its manufacturing and distribution facility in Roswell Georgia, which will significantly increase capa |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 ZOMEDICA CORP. Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 11, 2022 |
EXHIBIT 99.1 Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared ANN ARBOR, MI / ACCESSWIRE / July 6, 2022 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that the acquisition of the assets of Revo Squared LLC ('Revo') was recently completed. Rev |
|
| July 11, 2022 |
Warrant to Purchase Common Shares dated July 1, 2022 issued to Revo Squared LLC EXHIBIT 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 21, 2022 |
EXHIBIT 2.1 ASSET PURCHASE AGREEMENT BETWEEN REVO SQUARED LLC, THE PRINCIPAL MEMBER OF REVO SQUARED LLC (AS DEFINED HEREIN), ZOMEDICA INC. AND ZOMEDICA CORP. June 14, 2022 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1.1 Certain Definitions 1 1.2 Interpretation 9 ARTICLE II. PURCHASE AND SALE OF THE ACQUIRED ASSETS 10 2.1 Purchase and Sale of the Acquired Assets 10 2.2 Excluded Assets 11 2.3 Assumptio |
|
| June 21, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 21, 2022 |
ZOMEDICA TO ACQUIRE ASSETS OF INNOVATIVE VETERINARY IMAGING COMPANY REVO SQUARED EXHIBIT 99.1 HOLD FOR RELEASE UNTIL Wednesday June 15th ZOMEDICA TO ACQUIRE ASSETS OF INNOVATIVE VETERINARY IMAGING COMPANY REVO SQUARED ANN ARBOR, Mich., June 15, 2022 (Accesswire) ? Zomedica Corp. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has signed a definitive agreement |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 10, 2022 |
Exhibit 10.1 |
|
| May 10, 2022 |
EXHIBIT 99.1 Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues ANN ARBOR, Mich., May 10, 2022 (ACCESSWIRE) ? Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or ?Company?), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolida |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-Q ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022. |
|
| April 26, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 26, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as -permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stat |
|
| March 1, 2022 |
Summary of Compensation Arrangements with Ann Marie Cotter EXHIBIT 10.22 Summary of Compensation Arrangements With Ann Marie Cotter In connection with Ann Marie Cotter?s appointment as Interim Chief Financial Officer, Zomedica Corp. (the ?Company?) agreed to pay her a base salary of $200,000 per year. In June 2021, Ms. Cotter received an increase in base salary where her base salary was increased to $225,000 per year. Ms. Cotter is eligible to receive an |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| March 1, 2022 |
EXHIBIT 99.1 Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results Fourth Quarter 2021 PulseVet Revenue up 66% over Fourth Quarter 2020 ANN ARBOR, Mich., March 1, 2022 (Accesswire) ? Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or the ?Company?), a veterinary health company offering diagnostic and therapeutic products for companion animals, today reported consolidated financial re |
|
| March 1, 2022 |
EXHIBIT 21.1 Subsidiaries of Registrant Zomedica Inc., a Delaware corporation Branford PVT Acquiror, Inc., a Delaware corporation PVT Holdings, Inc., a Delaware corporation Pulse Veterinary Technologies, LLC, a Delaware limited liability company HMT High Medical Technologies (Japan) Co., Ltd., a Japanese company PVT NeoPulse Acquisition GmbH, a Swiss Company NeoPulse GmbH, a Swiss Company |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38298 ZOMEDICA CORP. |
|
| December 10, 2021 |
Unaudited Pro Forma Combined financial Information EXHIBIT 99.2 Unaudited Pro Forma Combined financial Information On October 1, 2021 (the ?Effective Date?), Zomedica Inc., a wholly-owned subsidiary of Zomedica Corp (?Zomedica? or the ?Company?), entered into a Stock Purchase Agreement (the ?Purchase Agreement?) with Branford PVT Mid-Hold, LLC (the ?Seller?) pursuant to which Zomedica Inc. acquired 100% of the capital stock of Branford PVT Acquiro |
|
| December 10, 2021 |
EXHIBIT 99.1 |
|
| December 10, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A ?Amendment No. 1? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS E |
|
| November 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 26, 2021 |
EXHIBIT 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE This Confidential Separation Agreement and Release (?Agreement?) is made by and between Br?k Herbst (?Employee?) and Zomedica Inc. (?Zomedica?). WHEREAS, Employee was an employee of Zomedica from July 17, 2017, until his employment ended on November 19, 2021; WHEREAS, Employee and Zomedica are parties to an Executive Employment Agreement d |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 12, 2021 |
EXHIBIT 10.2 1 2 |
|
| November 12, 2021 |
EXHIBIT 10.3 |
|
| November 12, 2021 |
Zomedica Announces Third Quarter 2021 Financial Results EXHIBIT 99.1 Zomedica Announces Third Quarter 2021 Financial Results ANN ARBOR, Mich., November 12, 2021 (Accesswire) ? Zomedica Corp. (NYSE American:ZOM) (?Zomedica? or ?Company?), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and nine months ended September 30, 2021. Amounts, unless specified |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. |
|
| October 4, 2021 |
EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of October 1, 2021 (the ?Effective Date?). AMONG: ZOMEDICA INC., a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the ?Corporation?); ZOMEDICA CORP., a body corporate duly incorporated pursuant to the law |
|
| October 4, 2021 |
Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan EXHIBIT 99.1 Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan ANN ARBOR, Mich., Oct. 04, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (?Zomedica? or the ?Company?), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that Larry Heaton has been appointed President effective October |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 1, 2021 |
EXHIBIT 99.1 Zomedica Acquires PulseVet ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (?Zomedica? or the ?Company?), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transactio |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 1, 2021 |
EX-2.1 2 exh21.htm EXHIBIT 2.1 Exhibit 2.1 STOCK PURCHASE AGREEMENT BETWEEN BRANFORD PVT MID-HOLD, LLC AND ZOMEDICA INC. OCTOBER 1, 2021 TABLE OF CONTENTS Page ARTICLE 1 STOCK PURCHASE; PURCHASE PRICE 1 Section 1.1 Purchase and Sale of the Purchased Shares. 1 Section 1.2 Closing. 2 Section 1.3 Closing Actions and Deliveries. 2 Section 1.4 Purchase Price Adjustment. 5 ARTICLE 2 REPRESENTATIONS AND |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 13, 2021 |
Sean Whelan Appointed to Board of Directors EXHIBIT 99.1 Sean Whelan Appointed to Board of Directors ANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (?Zomedica? or the ?Company?), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher |
|
| August 11, 2021 |
EXHIBIT 99.1 Zomedica Announces Second Quarter 2021 Financial Results TRUFORMA? Instrument Placement Program Implemented to Incentivize Future Assay Sales ANN ARBOR, Mich., Aug. 11, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (?Zomedica? or the ?Company?), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financia |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. |
|
| July 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| May 17, 2021 |
Separation Agreement between the Company and Stephanie Morley, dated May 14, 2021 Exhibit 10.1 AGREEMENT This Agreement ("Agreement") is made this 14th day of May, 2021, by and between Dr. Stephanie Morley ("Dr. Morley") and Zomedica Inc. (the "Company"), as well as any successor entities. WHEREAS, Dr. Morley and the Company are parties to an Executive Employment Agreement ("Employment Agreement"), dated September 16, 2019, and as amended on January 1, 2021; WHEREAS, the partie |
|
| May 17, 2021 |
Consulting Agreement between the Company and Stephanie Morley, dated May 14, 2021 Exhibit 10.2 Consulting Agreement This Agreement is made effective as of May 14, 2021, between Zomedica Inc. (the "Company") and Dr. Stephanie Morley ("Dr. Morley"). 1. Services. Dr. Morley is engaged to perform periodic consulting services related to business strategy, veterinary practice, the value of certain products and technology, trends in veterinary medicine, and similar topics at the Compa |
|
| May 17, 2021 |
EXHIBIT 99.1 Zomedica Hires Vice President Business Development to Lead Acquisition and Licensing Efforts Former Elanco Animal Health, Johnson & Johnson, Intuitive Surgical, and Enteromedics Business Development Executive Joins Team to Support Growth Opportunities ANN ARBOR, Mich., May 17, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (?Zomedica? or the ?Company?), a veterinary healt |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 12, 2021 |
EX-3.1 2 exh31.htm EXHIBIT 3.1 Exhibit 3.1 CORPORATE ACCESS NUMBER: 2019774088 Government o f Alb e rt a Ŷ BUSINESS CORPORATIONS ACT 0 CERTIFICATE OF AMENDMENT AND REGISTRATION OF RESTATED ARTICLES ZOMEDICA CORP. AMENDED ITS ARTICLES ON 2020/10/02. Articles Of Amendment Business Corporations Act Sectio n 2 7 or 171 Name of Corporation Corporate Access Number ZOMEDICA PHARMACEUTICALS CORP. 20197740 |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. |
|
| May 12, 2021 |
Zomedica Announces First Quarter 2021 Financial Results EXHIBIT 99.1 Zomedica Announces First Quarter 2021 Financial Results ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three months ended March 31, 2021. Amounts, unless specified otherwise, are |
|
| April 21, 2021 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 16, 2021 |
Zomedica Announces First Commercial Sale of Its Truforma® Platform EXHIBIT 99.1 Zomedica Announces First Commercial Sale of Its Truforma® Platform ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. “This is |
|
| March 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 16, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| March 8, 2021 |
Zomedica Retires Preferred Shares TRUFORMA® Progressing Toward Commercialization EXHIBIT 99.1 Zomedica Retires Preferred Shares TRUFORMA® Progressing Toward Commercialization ANN ARBOR, Mich., March 08, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has effected the exchange of all of its outstanding Series 1 Preferred S |
|
| March 5, 2021 |
As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 4, 2021 |
Exhibit 16.1 March 4, 2021 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have received a copy of, and are in agreement with, the statements being made by Zomedica Corp. in Item 4.01 of its Form 8-K dated February 26, 2021, captioned ?Changes in Registrant?s Certifying Accountant.? Chartered Professional Accountants Licensed Public Accountants |
|
| March 4, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38298 ZOMEDICA |
|
| February 26, 2021 |
Exhibit 10.11 INDEMNITY AGREEMENT This Agreement dated the th day of October, 2020. BETWEEN: ZOMEDICA CORP., a corporation, incorporated under the laws of the Province of Alberta, Canada (hereinafter called the ?Corporation?) OF THE FIRST PART - and - ?, an individual residing in ?,?, USA (hereinafter called ?Indemnified Party?) OF THE SECOND PART WHEREAS the Indemni?ed Party has agreed to act or |
|
| February 26, 2021 |
Zomedica Corp. Announces Year End 2020 Financial Results EXHIBIT 99.1 Zomedica Corp. Announces Year End 2020 Financial Results ANN ARBOR, Mich., Feb. 26, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, a |
|
| February 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 26, 2021 |
Exhibit 21.1 Subsidiaries of Registrant Zomedica Inc., a Delaware corporation |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2021 |
Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares Exhibit 99.1 Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC u |
|
| February 9, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-228926 PROSPECTUS SUPPLEMENT (to the Prospectus dated January 30, 2019) 91,315,790 Common Shares We are offering 91,315,790 of our common shares in this offering. Our common shares are listed on the NYSE American under the symbol “ZOM.” On February 8, 2021, the last reported sale price of our common shares on the NYSE American was $2.70 per sha |
|
| February 9, 2021 |
Free Writing Prospectus dated February 8, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 8, 2021 Registration Statement No. |
|
| February 9, 2021 |
Exhibit 99.2 Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, due to demand, the underwriter has agreed to increase |
|
| February 9, 2021 |
Exhibit 1.1 91,315,790 COMMON SHARES Zomedica Corp. AMENDED AND RESTATED UNDERWRITING AGREEMENT February 8, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: The undersigned, Zomedica Corp., an Alberta corporation (the “Company”), hereby confir |
|
| February 9, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| February 8, 2021 |
FWP 1 fwp020821.htm FWP Free Writing Prospectus dated February 8, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 8, 2021 Registration Statement No. 333-228926 Free Writing Prospectus Zomedica Corp. (the “Company”) has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to |
|
| February 8, 2021 |
SUBJECT TO COMPLETION DATED FEBRUARY 8, 2021 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zomedica Corp. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 98979F107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 19, 2021 |
Zomedica CEO Issues Shareholder Letter as TRUFORMA™ Nears Commercialization EXHIBIT 99.2 Zomedica CEO Issues Shareholder Letter as TRUFORMA™ Nears Commercialization ANN ARBOR, Mich., Jan. 18, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today issued the following letter from Robert Cohen, Chief Executive Officer, updating Zomedica’s shar |
|
| January 19, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 12, 2021 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 19, 2021 |
EXHIBIT 99.1 Tanya Hoos, CPA Senior Director NYSE Regulation 11 Wall Street New York, NY 10005 T +1 212 656 5391 [email protected] January 12, 2021 Robert Cohen Chief Executive Officer Zomedica Corp. 100 Phoenix Drive, Ste. 180 Ann Arbor, MI 48108 Dear Mr. Cohen: We are pleased to inform you that Zomedica Corp. (the “Company”) is back in compliance with NYSE American LLC continued listing stan |
|
| January 5, 2021 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of January 1, 2021 (the “Effective Date”). AMONG: ZOMEDICA PHARMACEUTICALS INC., a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the “Corporation”); ZOMEDICA CORP., f/k/a ZOMEDICA PHARMACUETICALS CORP., |
|
| January 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2021 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| December 23, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of the 16 day of September, 2019. BETWEEN: ZOMEDICA PHARMACEUTICALS INC., a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the "Corporation") - and – STEPHANIE MORLEY, an individual residing in [**] (here |
|
| December 23, 2020 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of the 1st day of July, 2017. BETWEEN: ZOMEDICA PHARMACEUTICALS INC., a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the "Corporation") - and - BRUK HERBST, an individual residing in [**] (hereinafter r |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| December 16, 2020 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 16, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 13, 2020 ZOMEDICA CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 16, 2020 |
EXHIBIT 99.1 Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™ Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point- |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2020 ZOMEDICA PHARMACEUTICALS CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 12, 2020 |
Zomedica Announces Third Quarter 2020 Financial Results EXHIBIT 99.1 Zomedica Announces Third Quarter 2020 Financial Results ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”) today reported consolidated financial results for the third quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accept |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. |
|
| October 26, 2020 |
425 1 f425102320.htm FORM 425 Filed by Zomedica Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Form S-4 File No.: 333-249401 Subject Company: Zomedica Corp. (SEC File No.: 001-38298) Dear Shareholders: I am writing to you today with a single, straightforward message - please vote for the domestication |
|
| October 26, 2020 |
ZOMEDICA CORP. PROPOSED DOMESTICATION—YOUR VOTE IS VERY IMPORTANT Filed pursuant to Rule 424(b)(3) Registration No. 333-249401 ZOMEDICA CORP. PROPOSED DOMESTICATION—YOUR VOTE IS VERY IMPORTANT Dear Shareholders: We are furnishing this proxy circular/prospectus to shareholders of Zomedica Corp. in connection with the solicitation of proxies by our management for use at a special meeting of our shareholders, or the Special Meeting, to be held on December 15, 2020 |
|
| October 22, 2020 |
Zomedica Corp. 100 Phoenix Drive, Suite 180 Ann Arbor, Michigan 48108 October 22, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Zomedica Corp. (the ?Company?) Registration Statement on Form S-4 (File No. 333- 249401) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as |
|
| October 22, 2020 |
As filed with the Securities and Exchange Commission on October 22, 2020 Registration No. |
|
| October 9, 2020 |
Certificate of Amendment and Registration of Restated Articles of Zomedica Corp. Exhibit 3.8 CORPORATE ACCESS NUMBER: 2019774088 BUSINESS CORPORATIONS ACT CERTIFICATE OF AMENDMENT AND REGISTRATION OF RESTATED ARTICLES ZOMEDICA CORP. AMENDED ITS ARTICLES ON 2020/10/02. Name/Structure Change Alberta Corporation - Registration Statement Alberta Amendment Date: 2020/10/02 Service Request Number: 34168735 Corporate Access Number: 2019774088 Business Number: 830376737 Legal Entity N |
|
| October 9, 2020 |
Letter Agreement, dated September 3, 2020, with Qorvo Biotechnologies, LLC Exhibit 10.10 18683 Bearpath Trail Eden Prairie, MN 55347 Telephone (612) 202-7026 [email protected] Robert Cohen Chief Executive Officer September 3, 2020 Mr. Hanjoon Ryu General Manager Qorvo Biotechnologies, LLC 14205 21st Avenue North (Suite 212) Plymouth, MN 55447 Dear Hanjoon: In partial fulfillment of the final Milestone Event set forth in Section 6.1 of the Development and Supply Agreeme |
|
| October 9, 2020 |
Exhibit 10.9 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. 18683 Bearpath Trail Eden Prairie, MN 55347 Telephone (612) 202-7026 [email protected] Robert Cohen Chief Executive Officer August 14, 2020 Mr. Ha |
|
| October 9, 2020 |
As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| September 28, 2020 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 ZOMEDICA PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38298 N/A (State or other jurisdiction (Commission (IRS Em |
|
| September 14, 2020 |
DEFA14A 1 defa14a091420.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| September 8, 2020 |
EXHIBIT 99.1 Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™ Three new assays to be added to the five assays currently under development ANN ARBOR, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) - Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that it has agreed with its development partner Qorvo Biotechnologies, LLC, a wholly owned subsidiary of Qorvo US, Inc., to de |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 8, 2020 ZOMEDICA PHARMACEUTICALS CORP. (Exact Name of Registrant as Specified in Charter) Alberta, Canada 001-38298 N/A (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 27, 2020 |
EXHIBIT 99.1 August 27, 2020 Dear Zomedica Shareholders: As I pass my second month anniversary at Zomedica, I have been looking forward to communicating with you directly and to offering both my impressions of the Company and an update on our progress. I am pleased to report that I have been impressed by what I have seen since assuming the CEO role. I believe that the core technology, planned prod |
|
| August 27, 2020 |
EXHIBIT 99.2 Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting ANN ARBOR, Mich., Aug. 27, 2020 (GLOBE NEWSWIRE) - Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders. D |
